FDA Clears IND Application for Experimental CAR T-Cell Therapy in Myasthenia Gravis
The biotechnology company Cabaletta Bio has recently announced that the company investigational new drug (IND) application for its experimental CD19-CAR T-cell therapy CABA-201 has been cleared by the US Food…